EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bruix, 2001, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver, J Hepatol, 35, 421, 10.1016/S0168-8278(01)00130-1
National Cancer Institute. PDQ® levels of evidence for adult and pediatric cancer treatment studies. Bethesda, MD: National Cancer Institute. Date last modified 26/August/2010. <http://cancer.gov/cancertopics/pdq/levels-evidence-adult-treatment/healthprofessional/>; 2011 [accessed 01.03.11].
IARC. <http://www-dep.iarc.fr/>; 2011 [accessed 01.11.11].
El-Serag, 1999, Rising incidence of hepatocellular carcinoma in the United States, N Engl J Med, 340, 745, 10.1056/NEJM199903113401001
Tanaka, 2008, Declining incidence of hepatocellular carcinoma in Osaka, Japan from 1990 to 2003, Ann Intern Med, 148, 820, 10.7326/0003-4819-148-11-200806030-00004
Bosetti, 2008, Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004, Hepatology, 48, 137, 10.1002/hep.22312
Chang, 2009, Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study, J Natl Cancer Inst, 101, 1348, 10.1093/jnci/djp288
Sangiovanni, 2006, The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients, Hepatology, 43, 1303, 10.1002/hep.21176
Ioannou, 2007, Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis, Clin Gastroenterol Hepatol, 5, 938, 10.1016/j.cgh.2007.02.039
Lok, 2009, Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease, Gastroenterology, 136, 138, 10.1053/j.gastro.2008.09.014
Ripoll, 2009, Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis, J Hepatol, 50, 923, 10.1016/j.jhep.2009.01.014
Masuzaki, 2009, Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography, Hepatology, 49, 1954, 10.1002/hep.22870
Jung, 2011, Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan), Hepatology, 53, 885, 10.1002/hep.24121
Lok, 2004, Prevention of hepatitis B virus-related hepatocellular carcinoma, Gastroenterology, 127, S303, 10.1053/j.gastro.2004.09.045
Yang, 2002, Taiwan Community–Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma, N Engl J Med, 347, 168, 10.1056/NEJMoa013215
Chen, 2006, REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, JAMA, 295, 65, 10.1001/jama.295.1.65
Yu, 2005, Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men, J Natl Cancer Inst, 97, 265, 10.1093/jnci/dji043
Iloeje, 2006, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer–In HBV (the REVEAL–HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130, 678, 10.1053/j.gastro.2005.11.016
Raimondi, 2009, Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis, J Hepatol, 50, 1142, 10.1016/j.jhep.2009.01.019
Hsu, 1991, Mutational hotspot in the p53 gene in human hepatocellular carcinomas, Nature, 350, 427, 10.1038/350427a0
Deugnier, 1993, Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases, Gastroenterology, 104, 228, 10.1016/0016-5085(93)90856-8
Perlmutter, 2006, Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency, Pediatr Res, 60, 233, 10.1203/01.pdr.0000228350.61496.90
Polio, 1989, Hepatocellular carcinoma in Wilson’s disease. Case report and review of the literature, J Clin Gastroenterol, 11, 220, 10.1097/00004836-198904000-00022
El-Serag, 2001, The role of diabetes in hepatocellular carcinoma: a case–control study among United States Veterans, Am J Gastroenterol, 96, 2462, 10.1111/j.1572-0241.2001.04054.x
Marrero, 2005, Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma, J Hepatol, 42, 218, 10.1016/j.jhep.2004.10.005
Trichopoulos, 2011, Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case–control study, J Natl Cancer Inst, 103, 1686, 10.1093/jnci/djr395
Marcellin, 2008, Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption, J Hepatol, 48, 200, 10.1016/j.jhep.2007.09.010
Miki, 1994, A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, 266, 66, 10.1126/science.7545954
Marra, 1995, Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives, J Natl Cancer Inst, 87, 1114, 10.1093/jnci/87.15.1114
Tanabe, 2008, Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis, JAMA, 299, 53, 10.1001/jama.2007.65
Clifford, 2010, Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma, Hepatology, 52, 2034, 10.1002/hep.23943
World Health Organization. Hepatitis B vaccines. Weekly epidemiological record of the World Health Organization 2009;84;405–420.
European Association for the Study of the Liver, 2009, EASL Clinical Practice Guidelines: management of chronic hepatitis B, J Hepatol, 50, 227, 10.1016/j.jhep.2008.10.001
European Association for the Study of the Liver, 2011, EASL Clinical Practice Guidelines: management of hepatitis C virus infection, J Hepatol, 55, 245, 10.1016/j.jhep.2011.02.023
Niederau, 1996, Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B, N Engl J Med, 334, 1422, 10.1056/NEJM199605303342202
Yuen, 2001, Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy, Hepatology, 34, 785, 10.1053/jhep.2001.27563
Liaw, 2004, Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, 351, 1521, 10.1056/NEJMoa033364
Singal, 2010, A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus, Clin Gastroenterol Hepatol, 8, 280, 10.1016/j.cgh.2009.11.018
Nishiguchi, 1995, Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis, Lancet, 346, 1051, 10.1016/S0140-6736(95)91739-X
Valla, 1999, Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment, Hepatology, 29, 1870, 10.1002/hep.510290616
Lok, 2011, HALT-C Trial Group. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C, Gastroenterology, 140, 840, 10.1053/j.gastro.2010.11.050
Di Bisceglie, 2011, HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon, Hepatology, 53, 1100, 10.1002/hep.24169
Bruix, 2011, EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C, Gastroenterology, 140, 1990, 10.1053/j.gastro.2011.03.010
Prorok, 1992, Epidemiologic approach for cancer screening. Problems in design and analysis of trials, Am J Pediatr Hematol Oncol, 14, 117, 10.1097/00043426-199205000-00005
Laupacis, 1992, How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations, CMAJ, 146, 473
Sarasin, 1996, Cost–effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child–Pugh class A cirrhosis, Am J Med, 101, 422, 10.1016/S0002-9343(96)00197-0
Fattovich, 2004, Hepatocellular carcinoma in cirrhosis: incidence and risk factors, Gastroenterology, 127, S35, 10.1053/j.gastro.2004.09.014
Yoshida, 1999, Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy, Ann Intern Med, 131, 174, 10.7326/0003-4819-131-3-199908030-00003
Sangiovanni, 2004, Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance, Gastroenterology, 126, 1005, 10.1053/j.gastro.2003.12.049
Ganne-Carrié, 1996, Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis, Hepatology, 23, 1112, 10.1002/hep.510230527
Velázquez, 2003, Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis, Hepatology, 37, 520, 10.1053/jhep.2003.50093
Trevisani, 2007, For the Italian Liver Cancer (ITA.LI.CA.) group. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?, Am J Gastroenterol, 102, 2448, 10.1111/j.1572-0241.2007.01395.x
Bruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199
Di Bisceglie, 2004, Issues in screening and surveillance for hepatocellular carcinoma, Gastroenterology, 127, S104, 10.1053/j.gastro.2004.09.022
Fattovich, 2008, Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors, J Hepatol, 48, 335, 10.1016/j.jhep.2007.11.011
Sánchez-Tapias, 2002, Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients, Gastroenterology, 123, 1848, 10.1053/gast.2002.37041
Bosch, 2004, Primary liver cancer: worldwide incidence and trends, Gastroenterology, 127, S5, 10.1053/j.gastro.2004.09.011
Yasui, 2011, Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma, Clin Gastroenterol Hepatol, 9, 428, 10.1016/j.cgh.2011.01.023
Craxì, 2005, Prevention of hepatocellular carcinoma, Clin Liver Dis, 9, 329, 10.1016/j.cld.2004.12.008
Bruno, 2007, Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study, Hepatology, 45, 579, 10.1002/hep.21492
Sung, 2008, Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma, Aliment Pharmacol Ther, 28, 1067, 10.1111/j.1365-2036.2008.03816.x
Lampertico, 2007, Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients, Gastroenterology, 133, 1445, 10.1053/j.gastro.2007.08.079
Bolondi, 2003, Screening for hepatocellular carcinoma in cirrhosis, J Hepatol, 39, 1076, 10.1016/S0168-8278(03)00349-0
Kim, 2001, Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients, J Ultrasound Med, 20, 99, 10.7863/jum.2001.20.2.99
Singal, 2009, Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis, Aliment Pharmacol Ther, 30, 37, 10.1111/j.1365-2036.2009.04014.x
Sato, 2009, Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C, Hepatol Int, 3, 544, 10.1007/s12072-009-9145-y
Lencioni, 2008, Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma, J Hepatol, 48, 848, 10.1016/j.jhep.2008.02.005
Marrero, 2003, Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients, Hepatology, 37, 1114, 10.1053/jhep.2003.50195
Tsukuma, 1993, Risk factors for hepatocellular carcinoma among patients with chronic liver disease, N Engl J Med, 328, 1797, 10.1056/NEJM199306243282501
Chen, 2003, Screening for liver cancer: results of a randomised controlled trial in Qidong, China, J Med Screen, 10, 204, 10.1258/096914103771773320
McMahon, 2000, Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study, Hepatology, 32, 842, 10.1053/jhep.2000.17914
Di Bisceglie, 2005, HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial, J Hepatol, 43, 434, 10.1016/j.jhep.2005.03.019
Yamashita, 2008, EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma, Cancer Res, 68, 1451, 10.1158/0008-5472.CAN-07-6013
Villanueva, 2010, Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy, Annu Rev Med, 61, 317, 10.1146/annurev.med.080608.100623
Hoshida, 2009, Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma, Cancer Res, 69, 7385, 10.1158/0008-5472.CAN-09-1089
Trevisani, 2001, Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and anti-HCV status, J Hepatol, 34, 570, 10.1016/S0168-8278(00)00053-2
Pateron, 1994, Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis, J Hepatol, 20, 65, 10.1016/S0168-8278(05)80468-4
Koike, 2001, Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients, Cancer, 91, 561, 10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N
Sterling, 2007, Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis, Am J Gastroenterol, 102, 2196, 10.1111/j.1572-0241.2007.01405.x
Wang, 2009, Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma, Cancer Epidemiol Biomarkers Prev, 18, 1914, 10.1158/1055-9965.EPI-08-0980
Zhang, 1999, Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer, J Med Screen, 6, 108, 10.1136/jms.6.2.108
Zhang, 2004, Randomized controlled trial of screening for hepatocellular carcinoma, J Cancer Res Clin Oncol, 130, 417, 10.1007/s00432-004-0552-0
Barbara, 1992, Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival, Hepatology, 16, 132, 10.1002/hep.1840160122
Ebara, 1986, Natural history of minute hepatocellular carcinoma smaller than three centimetres complicating cirrhosis. A study in 22 patients, Gastroenterology, 90, 289, 10.1016/0016-5085(86)90923-6
Sheu, 1985, Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications, Gastroenterology, 89, 259, 10.1016/0016-5085(85)90324-5
Makuuchi, 2008, Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan, Hepatol Res, 38, 37, 10.1111/j.1872-034X.2007.00216.x
Trinchet, 2011, Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities, Hepatology, 54, 1987, 10.1002/hep.24545
Santagostino, 2003, A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus, Blood, 102, 78, 10.1182/blood-2002-10-3310
Thompson Coon, 2007, Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis, Health Technol Assess, 11, 1, 10.3310/hta11340
Trevisani, 2004, Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis. Effects on cancer staging and patients survival, Am J Gastroenterol, 99, 1470, 10.1111/j.1572-0241.2004.30137.x
Nouso, 2008, Cost–effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances, J Gastroenterol Hepatol, 23, 437, 10.1111/j.1440-1746.2007.05054.x
Trevisani, 2002, Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patients survival (Italian experience), Am J Gastroenterol, 97, 734, 10.1111/j.1572-0241.2002.05557.x
Santi, 2010, Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival, J Hepatol, 53, 291, 10.1016/j.jhep.2010.03.010
Andersson, 2008, Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis, Clin Gastroenterol Hepatol, 6, 1418, 10.1016/j.cgh.2008.08.005
Lencioni, 2010, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin Liver Dis, 30, 52, 10.1055/s-0030-1247132
Roskams, 2011, Anatomic pathology impact on prognosis and response to therapy, Clin Liver Dis, 15, 245, 10.1016/j.cld.2011.03.004
Llovet, 2008, Novel advancements in the management of hepatocellular carcinoma in 2008, J Hepatol, 48, S20, 10.1016/j.jhep.2008.01.022
Bolondi, 2005, Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma, Hepatology, 42, 27, 10.1002/hep.20728
Forner, 2008, Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma, Hepatology, 47, 97, 10.1002/hep.21966
Roskams, 2010, Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis, Semin Liver Dis, 30, 17, 10.1055/s-0030-1247129
Terasaki, 1998, Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study, Gastroenterology, 115, 1216, 10.1016/S0016-5085(98)70093-9
Borzio, 2003, Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development, J Hepatol, 39, 208, 10.1016/S0168-8278(03)00190-9
Stigliano, 2007, Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC, Cancer Treat Rev, 33, 437, 10.1016/j.ctrv.2007.04.001
Sangiovanni, 2010, The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis, Gut, 59, 638, 10.1136/gut.2009.187286
Yu, 2011, CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis, Clin Gastroenterol Hepatol, 9, 161, 10.1016/j.cgh.2010.09.017
Sersté, 2011, Accuracy and disagreement of CT and MRI for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy, Hepatology
Rimola, 2009, Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma, Hepatology, 50, 791, 10.1002/hep.23071
International Consensus Group for Hepatocellular Neoplasia, 2009, Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia, Hepatology, 49, 658, 10.1002/hep.22709
Silva, 2008, Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis, Gut, 57, 1592, 10.1136/gut.2008.149062
Colombat, 2003, Quantitative RT-PCR in cirrhotic nodules reveals gene expression changes associated with liver carcinogenesis, J Pathol, 201, 260, 10.1002/path.1451
Llovet, 2006, A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis, Gastroenterology, 131, 1758, 10.1053/j.gastro.2006.09.014
Wurmbach, 2007, Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma, Hepatology, 45, 938, 10.1002/hep.21622
Di Tommaso, 2007, Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis, Hepatology, 45, 725, 10.1002/hep.21531
Capurro, 2003, Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma, Gastroenterology, 125, 89, 10.1016/S0016-5085(03)00689-9
Di Tommaso, 2009, The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma, J Hepatol, 50, 746, 10.1016/j.jhep.2008.11.014
Tremosini S, Forner A, Boix L, Rimola J, Rodríguez de Lope C, Reig M, et al. Biopsy diagnosis of hepatocellular carcinoma <2cm: prospective validation of glypican 3, heat-shock protein 70 and glutamine synthetase staining in fine needle biopsy samples. ILCA book of abstracts; 2011.
Durnez, 2006, The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin, Histopathology, 49, 138, 10.1111/j.1365-2559.2006.02468.x
Kim, 2011, Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis, Hepatology, 54, 1707, 10.1002/hep.24559
Colli, 2006, Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review, Am J Gastroenterol, 101, 513, 10.1111/j.1572-0241.2006.00467.x
Burrel, 2003, MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation, Hepatology, 38, 1034, 10.1002/hep.1840380430
D’Amico, 2006, Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies, J Hepatol, 44, 217, 10.1016/j.jhep.2005.10.013
Okuda, 1985, Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients, Cancer, 56, 918, 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E
The Cancer of the Liver Italian Program (CLIP) Investigators, 1998, A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients, Hepatology, 28, 751, 10.1002/hep.510280322
Llovet, 1999, Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials, Hepatology, 29, 62, 10.1002/hep.510290145
Villa, 2000, Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival, Hepatology, 32, 233, 10.1053/jhep.2000.9603
Cabibbo, 2010, A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma, Hepatology, 51, 1274, 10.1002/hep.23485
Simon, 2009, Use of archived specimens in evaluation of prognostic and predictive biomarkers, J Natl Cancer Inst, 101, 1446, 10.1093/jnci/djp335
Ji, 2009, MicroRNA expression, survival, and response to interferon in liver cancer, N Engl J Med, 361, 1437, 10.1056/NEJMoa0901282
Villanueva, 2011, Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma, Gastroenterology, 140, 1501, 10.1053/j.gastro.2011.02.006
Hoshida, 2008, Gene expression in fixed tissues and outcome in hepatocellular carcinoma, N Engl J Med, 359, 1995, 10.1056/NEJMoa0804525
Llovet, 2008, Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial. Presidential plenary session, AASLD 59th annual meeting, San Francisco, Hepatology, 48, 372A
Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047
Vibert, 2010, Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor, Am J Transplant, 10, 127, 10.1111/j.1600-6143.2009.02750.x
Toso, 2008, Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma, Liver Transpl, 8, 1107, 10.1002/lt.21484
N’Kontchou, 2009, Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis, Hepatology, 50, 1475, 10.1002/hep.23181
Riaz, 2009, Radiologic–pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres, Hepatology, 49, 1185, 10.1002/hep.22747
Vora, 2009, Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma, Oncologist, 14, 717, 10.1634/theoncologist.2009-0038
2010
Llovet, 1998, Liver transplantation for treatment of small hepatocellular carcinoma: the TNM classification does not have prognostic power, Hepatology, 27, 1572, 10.1002/hep.510270616
Chevret, 1999, A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire, J Hepatol, 31, 133, 10.1016/S0168-8278(99)80173-1
Llovet, 1999, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, 19, 329, 10.1055/s-2007-1007122
Llovet, 2008, Design and endpoints of clinical trials in hepatocellular carcinoma, J Natl Cancer Inst, 100, 698, 10.1093/jnci/djn134
Leung, 2002, Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients, Cancer, 94, 1760, 10.1002/cncr.10384
Kitai, 2008, Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score, Oncology, 75, S83, 10.1159/000173428
Marrero, 2005, Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort, Hepatology, 41, 707, 10.1002/hep.20636
Cillo, 2006, Prospective validation of the Barcelona Clinic Liver Cancer staging system, J Hepatol, 44, 723, 10.1016/j.jhep.2005.12.015
Guglielmi, 2008, Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response, Am J Gastroenterol, 103, 597, 10.1111/j.1572-0241.2007.01604.x
Kudo, 2007, Review of 4th Single Topic Conference on HCC. Hepatocellular carcinoma: international consensus and controversies, Hepatol Res, 37, S83, 10.1111/j.1872-034X.2007.00167.x
Takayama, 1998, Early hepatocellular carcinoma as an entity with a high rate of surgical cure, Hepatology, 28, 1241, 10.1002/hep.510280511
Roayaie, 2009, A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma, Gastroenterology, 137, 850, 10.1053/j.gastro.2009.06.003
Roayaie S, Llovet JM, Obeidat K, Labow D, Sposito C, Pellegrinelli A, et al. Hepatic resection for hepatocellular carcinoma <2cm in diameter. Hepatology, in press.
Livraghi, 2008, Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?, Hepatology, 47, 82, 10.1002/hep.21933
Arii, 2000, Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan, Hepatology, 32, 1224, 10.1053/jhep.2000.20456
Llovet, 1999, Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation, Hepatology, 30, 1434, 10.1002/hep.510300629
Sala, 2004, Barcelona Clínic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma, Hepatology, 40, 1352, 10.1002/hep.20465
Lopez, 2006, Systematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials, Aliment Pharmacol Ther, 23, 1535, 10.1111/j.1365-2036.2006.02932.x
Llovet, 2008, Molecular targeted therapies in hepatocellular carcinoma, Hepatology, 48, 1312, 10.1002/hep.22506
Takayasu, 2006, Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients, Gastroenterology, 131, 461, 10.1053/j.gastro.2006.05.021
Varela, 2007, Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics, J Hepatol, 46, 474, 10.1016/j.jhep.2006.10.020
Burrel M, Reig M, Forner A, Barrufet M, Rodríguez de Lope C, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using DC beads. Implications for clinical practice and trial design. J Hepatol, in press.
Llovet, 2008, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857
Raoul, 2011, Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization, Cancer Treat Rev, 37, 212, 10.1016/j.ctrv.2010.07.006
Huitzil-Melendez, 2010, Advanced hepatocellular carcinoma: which staging systems best predict prognosis?, J Clin Oncol, 28, 2889, 10.1200/JCO.2009.25.9895
Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101
Tsao, 2005, Erlotinib in lung cancer – molecular and clinical predictors of outcome, N Engl J Med, 353, 133, 10.1056/NEJMoa050736
Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, 363, 809, 10.1056/NEJMoa1002011
Boyault, 2007, Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets, Hepatology, 45, 42, 10.1002/hep.21467
Chiang, 2008, Focal gains of VEGFA and molecular classification of hepatocellular carcinoma, Cancer Res, 68, 6779, 10.1158/0008-5472.CAN-08-0742
Llovet, 2005, Resection and liver transplantation for hepatocellular carcinoma, Semin Liver Dis, 25, 181, 10.1055/s-2005-871198
Mazzaferro, 2011, Milan criteria in liver transplantation for HCC: an evidence-based analysis on 15 years of experience, Liver Transpl, 17, S44, 10.1002/lt.22365
Belghiti, 2000, Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection, J Am Coll Surg, 191, 38, 10.1016/S1072-7515(00)00261-1
Lang, 2005, Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis, Br J Surg, 92, 198, 10.1002/bjs.4763
Poon, 2002, Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified?, Ann Surg, 236, 602, 10.1097/00000658-200211000-00010
Mazzaferro, 2006, Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis, Hepatology, 44, 1543, 10.1002/hep.21415
Ishizawa, 2008, Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma, Gastroenterology, 134, 1908, 10.1053/j.gastro.2008.02.091
Makuuchi, 2004, The surgical approach to HCC: our progress and results in Japan, Liver Transpl, 10, S46, 10.1002/lt.20044
Arii, 2010, Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography, Oncology, 78, 125, 10.1159/000315240
Shi, 2007, Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial, Ann Surg, 245, 36, 10.1097/01.sla.0000231758.07868.71
Bruix, 1996, Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure, Gastroenterology, 111, 1018, 10.1016/S0016-5085(96)70070-7
Simpson, 1995, Clinical evaluation of liver disease Baillieres, Clin Gastroenterol, 9, 639
Cucchetti, 2009, Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population, Ann Surg Oncol, 16, 413, 10.1245/s10434-008-0232-4
Farges, 2003, Portal vein embolization before right hepatectomy: prospective clinical trial, Ann Surg, 237, 208, 10.1097/01.SLA.0000048447.16651.7B
Abulkhir, 2008, Preoperative portal vein embolization for major liver resection: a meta-analysis, Ann Surg, 247, 49, 10.1097/SLA.0b013e31815f6e5b
Croome, 2010, Laparoscopic vs open hepatic resection for benign and malignant tumors: an updated meta-analysis, Arch Surg, 145, 1109, 10.1001/archsurg.2010.227
Torzilli, 2004, Contrast-enhanced intraoperative ultrasonography in surgery for hepatocellular carcinoma in cirrhosis, Liver Transpl, 10, S34, 10.1002/lt.20050
Ikai, 2004, Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey, Cancer, 101, 796, 10.1002/cncr.20426
Vauthey, 2002, Simplified staging for hepatocellular carcinoma, J Clin Oncol, 20, 1527, 10.1200/JCO.20.6.1527
Belghiti, 1991, Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis, Ann Surg, 214, 114, 10.1097/00000658-199108000-00004
Finkelstein, 2003, Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma, Hepatology, 37, 871, 10.1053/jhep.2003.50134
Imamura, 2003, Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy, J Hepatol, 38, 200, 10.1016/S0168-8278(02)00360-4
Miyake, 2010, Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma, J Viral Hepat, 17, 287, 10.1111/j.1365-2893.2009.01181.x
Shen, 2010, Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach, J Hepatol, 52, 889, 10.1016/j.jhep.2009.12.041
Singal, 2010, Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy, Aliment Pharmacol Ther, 32, 969, 10.1111/j.1365-2036.2010.04427.x
Yamasaki, 1996, A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma, Jpn J Cancer Res, 87, 206, 10.1111/j.1349-7006.1996.tb03160.x
Lau, 1999, Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial, Lancet, 353, 797, 10.1016/S0140-6736(98)06475-7
Boucher, 2003, Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma, Hepatology, 38, 1237, 10.1053/jhep.2003.50473
Takayama, 2000, Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial, Lancet, 356, 802, 10.1016/S0140-6736(00)02654-4
Muto, 1996, Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group, N Engl J Med, 334, 1561, 10.1056/NEJM199606133342402
Okita K, Matsui O, Kumada H, Tanaka K, Kaneko S, Moriwaki H, et al. Peretinoin Study Group. Peretinoin reduces recurrence of hepatocellular carcinoma: results of a phase II/III randomized placebo-controlled trial. Book of Abstracts, ILCA 2010:11A.
Yoshida, 2011, Effect of vitamin K2 on the recurrence of hepatocellular carcinoma, Hepatology, 54, 532, 10.1002/hep.24430
Samuel, 2009, Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma, Cochrane Database Syst Rev, 21, CD001199
Iwatsuki, 1991, Hepatic resection versus transplantation for hepatocellular carcinoma, Ann Surg, 214, 221, 10.1097/00000658-199109000-00005
Iwatsuki, 1985, Liver transplantation for fulminant hepatic failure, Semin Liver Dis, 5, 325, 10.1055/s-2008-1040628
Mazzaferro, 1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056/NEJM199603143341104
Bismuth, 1999, Liver transplantation for hepatocellular carcinoma, Semin Liver Dis, 19, 311, 10.1055/s-2007-1007120
Bismuth, 1993, Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis, Ann Surg, 218, 145, 10.1097/00000658-199308000-00005
Jonas, 2001, Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis, Hepatology, 33, 1080, 10.1053/jhep.2001.23561
ELTR – European Liver Transplant Registry. <www.eltr.org/>; 2011 [accessed 03.11].
OPTN – Organ Procurement and Transplantation Network. <http://www.ustransplant.org/annual_reports/current/>; 2011 [accessed 02.11].
Freeman, 2002, UNOS/OPTN Liver Disease Severity Score, UNOS/OPTN Liver and Intestine, and UNOS/OPTN Pediatric Transplantation Committees. The new liver allocation system: moving toward evidence-based transplantation policy, Liver Transpl, 8, 851, 10.1053/jlts.2002.35927
Clavien, 2012, Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report, Lancet Oncol, 13, e11, 10.1016/S1470-2045(11)70175-9
Yao, 2001, Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival, Hepatology, 33, 1394, 10.1053/jhep.2001.24563
Kamath, 2001, A model to predict survival in patients with end-stage liver disease, Hepatology, 33, 464, 10.1053/jhep.2001.22172
Pomfret, 2010, Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States, Liver Transpl, 16, 262, 10.1002/lt.21999
Sala, 2004, High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation, Liver Transpl, 10, 1294, 10.1002/lt.20202
Mazzaferro, 2004, Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study, Ann Surg, 240, 900, 10.1097/01.sla.0000143301.56154.95
Lu, 2005, Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation, Hepatology, 41, 1130, 10.1002/hep.20688
Majno, 1997, Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis, Ann Surg, 226, 688, 10.1097/00000658-199712000-00006
Decaens, 2005, Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma, Liver Transpl, 11, 767, 10.1002/lt.20418
Porrett, 2006, Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era, Liver Transpl, 12, 665, 10.1002/lt.20636
Llovet, 2002, Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation, Gut, 50, 123, 10.1136/gut.50.1.123
Vitale, 2010, Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost–benefit analysis while awaiting data on sorafenib safety, Hepatology, 51, 165, 10.1002/hep.23260
Truesdale, 2011, Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant, Transpl Int, 24, 991, 10.1111/j.1432-2277.2011.01299.x
Yao, 2007, Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging, Am J Transplant, 7, 2587, 10.1111/j.1600-6143.2007.01965.x
Mazzaferro, 2009, Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis, Lancet Oncol, 10, 35, 10.1016/S1470-2045(08)70284-5
Raj, 2011, Validation of the “Metroticket” predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma, J Hepatol, 55, 1063, 10.1016/j.jhep.2011.01.052
Germani, 2011, Which matters most: number of tumors, size of the largest tumor, or total tumor volume?, Liver Transpl, 17, S58, 10.1002/lt.22336
Schwartz, 2008, Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers, J Hepatol, 49, 581, 10.1016/j.jhep.2008.03.032
Yao, 2008, Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis, Hepatology, 48, 819, 10.1002/hep.22412
Ravaioli, 2008, Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria, Am J Transplant, 8, 2547, 10.1111/j.1600-6143.2008.02409.x
Neuberger, 2010, Liver allocation for patients with hepatocellular carcinoma, Liver Transpl, 16, 249
Bhoori, 2010, The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis, Transpl Int, 23, 712, 10.1111/j.1432-2277.2010.01111.x
Trotter, 2002, Adult-to-adult transplantation of the right hepatic lobe from a living donor, N Engl J Med, 346, 1074, 10.1056/NEJMra011629
Clavien, 2007, Strategies for safer liver surgery and partial liver transplantation, N Engl J Med, 356, 1545, 10.1056/NEJMra065156
Bruix, 2002, Prognostic prediction and treatment strategy in hepatocellular carcinoma, Hepatology, 35, 519, 10.1053/jhep.2002.32089
Siegler, 2006, Recipient deaths during donor surgery: a new ethical problem in living donor liver transplantation (LDLT), Liver Transpl, 12, 358, 10.1002/lt.20670
Ghobrial, 2008, A2ALL Study Group. Donor morbidity after living donation for liver transplantation, Gastroenterology, 135, 468, 10.1053/j.gastro.2008.04.018
Browns, 2008, Live donors in liver transplantation, Gastroenterology, 134, 1802, 10.1053/j.gastro.2008.02.092
Cronin, 2008, Living donor liver transplantation: the ethics and the practice, Hepatology, 47, 11, 10.1002/hep.22150
Sarasin, 2001, Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost–effectiveness perspective, Hepatology, 33, 1073, 10.1053/jhep.2001.23311
Lo, 2007, Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma, Br J Surg, 94, 78, 10.1002/bjs.5528
Fisher, 2007, A2ALL Study Group. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation, Am J Transplant, 7, 1601, 10.1111/j.1600-6143.2007.01802.x
Kulik, 2004, Living donor liver transplantation for hepatocellular carcinoma, Gastroenterology, 127, S277, 10.1053/j.gastro.2004.09.042
Majno, 2006, Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: questions, answers and demands for a common language, Liver Transpl, 12, 896, 10.1002/lt.20808
Lencioni, 2010, Loco-regional treatment of hepatocellular carcinoma, Hepatology, 52, 762, 10.1002/hep.23725
Livraghi, 1992, Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients, Cancer, 15, 925, 10.1002/1097-0142(19920215)69:4<925::AID-CNCR2820690415>3.0.CO;2-G
Kuang, 2009, Percutaneous ethanol ablation of early-stage hepatocellular carcinoma by using a multi-pronged needle with single treatment session and high-dose ethanol injection, Radiology, 253, 552, 10.1148/radiol.2532082021
Lencioni, 1995, Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients, Cancer, 76, 1737, 10.1002/1097-0142(19951115)76:10<1737::AID-CNCR2820761010>3.0.CO;2-P
Livraghi, 1995, Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection, Radiology, 197, 101, 10.1148/radiology.197.1.7568806
Khan, 2000, Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection, J Hepatol, 32, 269, 10.1016/S0168-8278(00)80072-0
Huo, 2003, Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study, Scand J Gastroenterol, 38, 770, 10.1080/00365520310003048
Lin, 2005, Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less, Gut, 54, 1151, 10.1136/gut.2004.045203
Shiina, 2005, A randomized controlled trial of radiofrequency ablation versus ethanol injection for small hepatocellular carcinoma, Gastroenterology, 129, 122, 10.1053/j.gastro.2005.04.009
Lin, 2004, Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4cm, Gastroenterology, 127, 1714, 10.1053/j.gastro.2004.09.003
Lencioni, 2003, Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection, Radiology, 228, 235, 10.1148/radiol.2281020718
Brunello, 2008, Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial, Scand J Gastroenterol, 43, 727, 10.1080/00365520701885481
Cho, 2009, Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies, Hepatology, 49, 453, 10.1002/hep.22648
Germani, 2010, Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis, J Hepatol, 52, 380, 10.1016/j.jhep.2009.12.004
Bouza, 2009, Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma, BMC Gastroenterol, 9, 31, 10.1186/1471-230X-9-31
Imamura, 2008, Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma, Am J Gastroenterol, 103, 3057, 10.1111/j.1572-0241.2008.02153.x
Lencioni, 2005, Early-stage hepatocellular carcinoma in cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation, Radiology, 234, 961, 10.1148/radiol.2343040350
Omata, 2004, Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation, Gastroenterology, 127, S159, 10.1053/j.gastro.2004.09.030
Lencioni, 2005, Percutaneous ethanol injection in hepatocellular carcinoma: alive or dead, J Hepatol, 43, 377, 10.1016/j.jhep.2005.06.001
Chen, 2006, A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma, Ann Surg, 243, 321, 10.1097/01.sla.0000201480.65519.b8
Huang, 2010, A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria, Ann Surg, 252, 903, 10.1097/SLA.0b013e3181efc656
Lu, 2005, Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver, Radiology, 234, 954, 10.1148/radiol.2343040153
Komorizono, 2003, Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation, Cancer, 97, 1253, 10.1002/cncr.11168
Llovet, 2001, Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma, Hepatology, 33, 1124, 10.1053/jhep.2001.24233
Teratani, 2006, Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations, Hepatology, 43, 1101, 10.1002/hep.21164
Yu, 2006, Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters – pilot comparison with pathologic findings, Radiology, 239, 269, 10.1148/radiol.2383041592
Shibata, 2002, Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy, Radiology, 223, 331, 10.1148/radiol.2232010775
Pacella, 2009, Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis, J Clin Oncol, 27, 2615, 10.1200/JCO.2008.19.0082
Orlacchio, 2008, Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience, Cardiovasc Intervent Radiol, 31, 587, 10.1007/s00270-008-9293-9
Guo, 2010, Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma, Cancer Res, 70, 1555, 10.1158/0008-5472.CAN-09-3067
Ng, 2011, High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience, Ann Surg, 253, 981, 10.1097/SLA.0b013e3182128a8b
Wang, 2009, A phase 1/2 safety and efficacy study of intratumoral light-activated drug therapy using talaporfin sodium in patients with inoperable hepatocellular carcinoma, J Clin Oncol, 27A
Bruix, 2004, Chemoembolization for hepatocellular carcinoma, Gastroenterology, 127, S179, 10.1053/j.gastro.2004.09.032
Brown, 2009, Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-Guided Tumor Ablation. Image-guided tumor ablation: standardization of terminology and reporting criteria, J Vasc Interv Radiol, 20, S377, 10.1016/j.jvir.2009.04.011
Lin, 1988, Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma – a randomized controlled trial, Gastroenterology, 94, 453, 10.1016/0016-5085(88)90436-2
Pelletier, 1990, A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma, J Hepatol, 11, 181, 10.1016/0168-8278(90)90110-D
Group d’Etude et de Traitment du Carcinome Hépatocellulaire, 1995, A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma, N Engl J Med, 332, 1256, 10.1056/NEJM199505113321903
Bruix, 1998, Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution, Hepatology, 27, 1578, 10.1002/hep.510270617
Pelletier, 1998, Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial, J Hepatol, 29, 129, 10.1016/S0168-8278(98)80187-6
Lo, 2002, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 35, 1164, 10.1053/jhep.2002.33156
Llovet, 2002, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 359, 1734, 10.1016/S0140-6736(02)08649-X
Oliveri, 2011, Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma, Cochrane Database Syst Rev, 3, CD004787
Lammer, 2010, Prospective randomised study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc Intervent Radiol, 33, 41, 10.1007/s00270-009-9711-7
Raoul, 1997, Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma, Hepatology, 26, 1156
Salem, 2010, Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes, Gastroenterology, 138, 52, 10.1053/j.gastro.2009.09.006
Kulik, 2008, Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis, Hepatology, 47, 71, 10.1002/hep.21980
Hilgard, 2010, Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival, Hepatology, 52, 1741, 10.1002/hep.23944
Sangro, 2009, Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres, Dig Dis, 27, 164, 10.1159/000218349
Cheng, 2002, Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description, Radiother Oncol, 63, 41, 10.1016/S0167-8140(02)00061-0
Ben-Josef, 2005, Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies, J Clin Oncol, 23, 8739, 10.1200/JCO.2005.01.5354
Sridhara, 2010, Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007, J Natl Cancer Inst, 102, 230, 10.1093/jnci/djp515
Farazi, 2006, Hepatocellular carcinoma pathogenesis: from genes to environment, Nat Rev Cancer, 6, 674, 10.1038/nrc1934
Villanueva, 2007, Genomics and signaling pathways in hepatocellular carcinoma, Semin Liver Dis, 27, 55, 10.1055/s-2006-960171
Roberts, 2005, Hepatocellular carcinoma: molecular pathways and new therapeutic targets, Semin Liver Dis, 25, 212, 10.1055/s-2005-871200
Semela, 2004, Angiogenesis and hepatocellular carcinoma, J Hepatol, 41, 864, 10.1016/j.jhep.2004.09.006
Ito, 2001, Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma, Br J Cancer, 84, 1377, 10.1054/bjoc.2000.1580
Calvisi, 2006, Ubiquitous activation of Ras and Jak/Stat pathways in human HCC, Gastroenterology, 130, 1117, 10.1053/j.gastro.2006.01.006
Robinson, 2000, The protein tyrosine kinase family of the human genome, Oncogene, 19, 5548, 10.1038/sj.onc.1203957
Wilhelm, 2008, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling, Mol Cancer Ther, 7, 3129, 10.1158/1535-7163.MCT-08-0013
Villanueva, 2008, Pivotal role of mTOR signaling in hepatocellular carcinoma, Gastroenterology, 135, 1972, 10.1053/j.gastro.2008.08.008
Sahin, 2004, MTOR and P70 S6 kinase expression in primary liver neoplasms, Clin Cancer Res, 10, 8421, 10.1158/1078-0432.CCR-04-0941
Takami, 2007, Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis, Cancer Res, 67, 9844, 10.1158/0008-5472.CAN-07-1905
Breuhahn, 2006, Dysregulation of growth factor signaling in human hepatocellular carcinoma, Oncogene, 25, 3787, 10.1038/sj.onc.1209556
Tovar, 2010, IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage, J Hepatol, 52, 550, 10.1016/j.jhep.2010.01.015
De La Coste, 1998, Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas, Proc Natl Acad Sci USA, 95, 8847, 10.1073/pnas.95.15.8847
Zucman-Rossi, 2007, Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas, Oncogene, 26, 774, 10.1038/sj.onc.1209824
Colnot, 2004, Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas, Proc Natl Acad Sci USA, 101, 17216, 10.1073/pnas.0404761101
Toffanin, 2011, MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a, Gastroenterology, 140, 1618, 10.1053/j.gastro.2011.02.009
Villanueva, 2011, Targeted therapies for hepatocellular carcinoma, Gastroenterology, 140, 1410, 10.1053/j.gastro.2011.03.006
Abou-Alfa, 2006, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 24, 4293, 10.1200/JCO.2005.01.3441
Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7
Kim, 2011, Sorafenib for hepatocellular carcinoma according to Child–Pugh class of liver function, Cancer Chemother Pharmacol, 68, 1285, 10.1007/s00280-011-1616-x
Hollebecque, 2011, Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child–Pugh score, Aliment Pharmacol Ther, 34, 1193, 10.1111/j.1365-2036.2011.04860.x
Dufour, 2010, Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study, Oncologist, 15, 1198, 10.1634/theoncologist.2010-0180
Abou-Alfa, 2010, Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial, JAMA, 304, 2154, 10.1001/jama.2010.1672
Decaens, 2008, Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma, J Hepatol, 48, S13, 10.1016/S0168-8278(08)60030-6
Philip, 2005, Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer, J Clin Oncol, 23, 6657, 10.1200/JCO.2005.14.696
Bekaii-Saab, 2009, A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas, Clin Cancer Res, 15, 5895, 10.1158/1078-0432.CCR-09-0465
Faivre, 2009, Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study, Lancet Oncol, 10, 794, 10.1016/S1470-2045(09)70171-8
Zhu, 2009, Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study, J Clin Oncol, 27, 3027, 10.1200/JCO.2008.20.9908
Koeberle, 2010, Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06), Oncologist, 15, 285, 10.1634/theoncologist.2009-0316
Cheng, 2011, Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC), J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.4000
Park, 2011, Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma, Clin Cancer Res, 17, 1973, 10.1158/1078-0432.CCR-10-2011
Siegel, 2008, Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma, J Clin Oncol, 26, 2992, 10.1200/JCO.2007.15.9947
Thomas, 2009, Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma, J Clin Oncol, 27, 843, 10.1200/JCO.2008.18.3301
Zhu, 2006, Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma, J Clin Oncol, 24, 1898, 10.1200/JCO.2005.04.9130
Spratlin, 2010, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, J Clin Oncol, 28, 780, 10.1200/JCO.2009.23.7537
Taieb, 2006, Medical treatments for hepatocellular carcinoma (HCC): what’s next?, Ann Oncol, 10, 308, 10.1093/annonc/mdl279
Gish, 2007, Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin, J Clin Oncol, 25, 3069, 10.1200/JCO.2006.08.4046
Yeo, 2005, A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma, J Natl Cancer Inst, 97, 1532, 10.1093/jnci/dji315
Qin, 2010, Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients, J Clin Oncol, 28, 4008A, 10.1200/jco.2010.28.15_suppl.4008
Edeline, 2009, Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study, World J Gastroenterol, 15, 713, 10.3748/wjg.15.713
Barbare, 2005, Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma, J Clin Oncol, 23, 4338, 10.1200/JCO.2005.05.470
Chow, 2002, Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial, Hepatology, 36, 1221, 10.1053/jhep.2002.36824
Grimaldi, 1998, Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial, J Clin Oncol, 16, 411, 10.1200/JCO.1998.16.2.411
Greten, 2006, Immunotherapy of hepatocellular carcinoma, J Hepatol, 45, 868, 10.1016/j.jhep.2006.09.004
Beaugrand, 2003, Treatment of advanced hepatocellular carcinoma by seocalcitol: an international randomized double-blind placebo-controlled study in 747 patients, J Hepatol, 42, 17A
Posey, 2005, Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin in chemotherapy-naive, unresectable hepatocellular carcinoma, J Clin Oncol, 23, 316, 10.1200/jco.2005.23.16_suppl.4035
Cheng, 2008, Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3cm. A randomized controlled trial, JAMA, 299, 1669, 10.1001/jama.299.14.1669
Miller, 1981, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205
Bogaerts, 2009, RECIST Working Party. Individual patient data analysis to assess modifications to the RECIST criteria, Eur J Cancer, 45, 248, 10.1016/j.ejca.2008.10.027
Forner, 2009, Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?, Cancer, 115, 616, 10.1002/cncr.24050
Gillmore, 2011, EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization, J Hepatol, 55, 1309, 10.1016/j.jhep.2011.03.007
Lambert, 2011, Intra-arterial treatment with (90)Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital, Eur J Nucl Med Mol Imaging, 38, 2117, 10.1007/s00259-011-1881-2
Iavarone, 2011, Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy, Hepatology, 54, 2055, 10.1002/hep.24644
Edeline, 2011, Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma, Cancer